Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11929775 | 0.97 | CTSS (0.50) | CTSSCTSBCYP3A4 | |
| SCHEMBL11929849 | 0.96 | CTSS (0.57) | CTSSCTSBCYP3A4 | |
| SCHEMBL11929846 | 0.90 | CTSS (0.58) | CTSSCTSB | |
| SCHEMBL11929866 | 0.90 | CTSS (0.50) | CTSSCTSBCYP3A4 | |
| SCHEMBL6844934 | 0.87 | CTSS (0.69) | CTSSCTSBCYP3A4 | |
| SCHEMBL3063876 | 0.86 | CTSS (0.42) | CTSSCTSBCYP3A4 | |
| SCHEMBL3063879 | 0.86 | CTSS (0.42) | CTSSCTSBCYP3A4 | |
| SCHEMBL13090648 | 0.86 | CTSS (0.42) | CTSSCTSBCYP3A4 | |
| SCHEMBL11929370 | 0.86 | CTSS (0.62) | CTSSCTSBCYP3A4 | |
| SCHEMBL6844902 | 0.86 | CTSS (0.60) | CTSSCTSBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353100-B2 | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-20120207703-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING HCV INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120207703-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING HCV INFECTIONS | PRSS1, SERPINB1, SPINT2 | CTSS 35/4885CTSB 48/4885CYP3A4 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.